Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2016

View Archived Issues

Valneva develops Zika virus vaccine

Phase III S-TRAC study of sunitinib meets primary endpoint

Design of a novel dimeric compound that targets the pathogenic RNA in spinocerebellar ataxia 10

Results from phase III LUNAR study of LBN 0.024% in open-angle glaucoma or ocular hypertension

Anti-tau antibody enters phase I trials, AC Immune eligible to receive milestone payment

Proteostasis Therapeutics patents CFTR channel correctors

Gilead Sciences obtains European marketing authorization for Epclusa

Evotec collaborates with Antibiotic Research UK to tackle antibiotic resistance

Ligand Pharmaceuticals and Gilead Sciences enter OmniAb agreement

FDA approves use of SurePath Preservative Fluid with cobas HPV Test

Ono Pharmaceutical discloses AXL inhibitors

Nichi-Iko Pharmaceutical to acquire Sagent Pharmaceuticals

Gilead Sciences describes HIV reverse transcriptase inhibitors

Merck & Co. develops orexin OX2 receptor antagonists

LG Life Sciences presents FFAR4 agonists

Multiple doses of intravenous echinocandin CD-101 safe and well tolerated in phase I study

Alios BioPharma announces agents for picornavirus infections

Regulatory submissions planned for niraparib following phase III results

Vernalis completes CCP-08 study

Topline results from pivotal European study of Infacort in pediatric adrenal insufficiency

Ono Pharmaceutical licenses rights to Celyad's NKR-2 in Japan, South Korea and Taiwan

GlyRS shows promise as a therapeutic target for cancer

FDA grants orphan drug designation to ZW-33

Karyopharm's selinexor granted U.S. orphan status for soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026